MedTrace Logo

Intravascular Volumes in Hypoxia During Antarctic Confinement

NCT04106401 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-09-13

No results posted yet for this study

Summary

This study evaluates the effect of hypoxia on blood volumes during Antarctic winter-over confinement. Half of the participants will be evaluated during sea-level winter-over confinement, while the other half will be examined during high-altitude hypoxia winter-over confinement.

Conditions

Interventions

OTHER

carbon-monoxide rebreathing

Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.

OTHER

venous blood sampling

venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism

OTHER

physical activity monitoring

recording of physical activity by actimetry

OTHER

apnea-hypopnea index and nocturnal oxygenation

recorded by ambulatory sleep recording device

OTHER

24-hour blood pressure

recorded by ambulatory device

Sponsors & Collaborators

  • Center for Physical Activity Research, University Hospital of Copenhagen, Denmark

    collaborator UNKNOWN

  • Laboratory Mobility, aging & exercise (MOVE) -EA 6314, Faculty of Sport Sciences, University of Poitiers, France

    collaborator UNKNOWN

  • Department for Biomedical Sciences for Health, University of Milan School of Medicine, Milan, Italy

    collaborator UNKNOWN

  • HP2 Laboratory, INSERM, Grenoble Alpes University, CHU Grenoble Alpes, Grenoble, France

    collaborator UNKNOWN

  • Ecole Nationale des Sports de Montagne

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04106401 on ClinicalTrials.gov